Updated 10 November 2026. Educational content only; individual clinical care requires current local guidelines and product labeling.
Overview
Cardiac glycosides and parenteral inotropes increase cardiac contractility through different mechanisms. They are not foundational mortality-reducing treatment for most patients with chronic heart failure with reduced ejection fraction (HFrEF): evidence-based neurohormonal therapies remain essential. Digoxin has selected roles in symptomatic HFrEF and atrial-fibrillation rate control; IV inotropes are generally reserved for shock, severe low-output states, or specialist palliative/bridge strategies [1, 2, 3].
Drug classes and mechanisms
- Cardiac glycosides: digoxin, digitoxin and historically ouabain possess a steroid core, sugar moieties and an unsaturated lactone. Digoxin inhibits myocardial Na+/K+-ATPase, raising intracellular sodium and reducing sodium/calcium exchange, increasing intracellular calcium and contractility. Vagal effects slow AV-nodal conduction.
- Beta-1 adrenergic inotrope: dobutamine increases cAMP/PKA signaling, calcium influx and contractility, with variable vascular and chronotropic effects.
- Phosphodiesterase-3 inhibitor: milrinone increases intracellular cAMP in myocardium and vascular smooth muscle, yielding inotropy and vasodilation.
- Vasopressor with inotropic effects: norepinephrine primarily supports vascular tone in shock and may provide beta-1 stimulation, but it is not interchangeable with dobutamine [1, 2].
Clinical indications and limits
In symptomatic HFrEF despite guideline-directed medical therapy, digoxin can be considered to reduce HF hospitalizations but has not demonstrated overall survival benefit. In atrial fibrillation, digoxin can aid ventricular rate control, especially when beta blockers or nondihydropyridine calcium-channel blockers are unsuitable; onset and efficacy during exertion differ. Dobutamine or milrinone may support selected patients with cardiogenic shock and documented hypoperfusion under intensive monitoring, but can provoke arrhythmia and hypotension [2, 3].
Pharmacokinetics and monitoring
Digoxin is predominantly renally cleared and has a narrow therapeutic index; dosing is affected by age, lean body mass, kidney function and interacting drugs. Milrinone is substantially renally eliminated and requires renal-dose review. Dobutamine is short acting and administered by titrated IV infusion [1, 2].
Toxicity and interactions
Digoxin toxicity may cause nausea, visual changes, confusion and brady- or tachyarrhythmias. Hypokalemia and hypomagnesemia increase risk. Amiodarone, verapamil and selected P-glycoprotein inhibitors increase digoxin exposure. Life-threatening digoxin toxicity may require digoxin immune Fab and specialist resuscitation. Dobutamine and milrinone can provoke tachyarrhythmias, myocardial ischemia and hypotension; invasive hemodynamic assessment may be needed [1, 2, 3].
Interpreting a digoxin level
Record when the last dose was taken. A sample drawn during the early distribution phase can be misleadingly high. Draw just before the next dose or at least six hours after the previous dose. For heart failure, the US guideline lists a target serum concentration of 0.5 to below 0.9 ng/mL. Interpret the result alongside the ECG, symptoms, kidney function, potassium, magnesium and interacting medicines. A concentration within the target range cannot by itself exclude toxicity. [4, 2]
A decline in kidney function can increase digoxin exposure, while hypokalaemia can increase susceptibility at a given concentration. Nausea, appetite loss, visual changes, bradycardia or a new arrhythmia warrant assessment. Life-threatening digoxin toxicity can require digoxin immune Fab. After Fab, standard total digoxin assays also measure bound drug and can remain misleadingly high. Follow the clinical response, ECG and potassium. [4, 5]
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation. 2022;145:e895–e1032. doi:10.1161/CIR.0000000000001063. Available from: https://doi.org/10.1161/CIR.0000000000001063
- Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for diagnosis and management of atrial fibrillation. Circulation. 2024;149:e1–e156. doi:10.1161/CIR.0000000000001193. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11095842/
- US Food and Drug Administration. Lanoxin (digoxin) tablets. Prescribing information. View source.
- US Food and Drug Administration. DigiFab (digoxin immune Fab [ovine]). Package insert. View source.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.